The Lancet· @TheLancet · X·· 9 小时前AI 评分22
AI 导读
GLP-1 受体激动剂（RA）正在改变糖尿病和肥胖症的治疗。女性是主要使用者，但使用速度已超出指南。The Lancet Obstetrics, Gynaecology, and Women's Health 上的两篇论文探讨了女性 GLP-1RA 治疗：可及性、安全性和公平性。#EASD2026 阅读更多：http://spkl.io/60147p5i2
正文
GLP-1 receptor agonists (RA) are transforming diabetes and obesity. Women are the predominant users, but uptake has outpaced guidance. Two papers in The Lancet Obstetrics, Gynaecology, and Women’s Health explore GLP-1RA treatment in women: access, safety, and equity. #EASD2026
Read more: http://spkl.io/60147p5i2
来源：The Lancet · x.com